P375 To evaluate the effectiveness of primary prevention of anthracycline cardiotoxicity using modern STE technologies
Nesvetov V, Vasyuk Y, Shkolnik E, Yushuk E. P375 To evaluate the effectiveness of primary prevention of anthracycline cardiotoxicity using modern STE technologies. European Heart Journal - Cardiovascular Imaging 2020, 21 DOI: 10.1093/ehjci/jez319.223.Peer-Reviewed Original ResearchPrevention of anthracycline cardiotoxicityAnthracycline cardiotoxicityBreast cancerLeft ventricleMonths of follow-upSubclinical systolic dysfunctionLV ejection fractionEffects of ivabradineGlobal longitudinal strainCollection of anamnesisAppearance of clinical manifestationsControl groupHeart rateDevelopment of cardiomyopathySix-month treatmentHeart rate >Beats per minuteSystolic dysfunctionEjection fractionEchocardiographic indicesPrescribed chemotherapyDaily doseClinical manifestationsChemotherapeutic drugsHeart failure
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply